anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the field of pulmonary hypertension (PH), a well-established protocol to induce severe angioproliferation in rats (SuHx) involves combining the VEGF-R inhibitor Sugen 5416 (SU5416) with 3 wk of hypoxia (Hx). In addition, injecting monocrotaline (MCT) into rats can induce inflammation and shear stress in the pulmonary vasculature, leading to neointima-like remodeling. However, the SuHx protocol in mice is still controversial, with some studies suggesting it yields higher and reversible PH than Hx alone, possibly due to species-dependent hypoxic responses. To establish an alternative rodent model of PH, we hypothesized mice would be more sensitive to hemodynamic changes secondary to shear stress compared with Hx. We attempted to induce severe and irreversible PH in mice by combining SU5416 or monocrotaline pyrrole (MCTP) injection with pneumonectomy (PNx). However, our experiments showed SU5416 administered to mice at various time points after PNx did not result in severe PH. Similarly, mice injected with MCTP after PNx (MPNx) showed no difference in right ventricular systolic pressure or exacerbated pulmonary vascular remodeling compared with PNx alone. These findings collectively demonstrate that C57/B6 mice do not develop severe and persistent PH when PNx is combined with either SU5416 or MCTP.NEW & NOTEWORTHY We attempted to establish a mouse model of severe and irreversible pulmonary hypertension by substituting hypoxia with pulmonary overcirculation. To do so, we treated mice with either SU5416 or monocrotaline pyrrole after pneumonectomy and performed hemodynamic evaluations for PH. Despite this "two-hit" protocol, mice did not exhibit signs of severe pulmonary hypertension or exacerbated pulmonary vascular remodeling compared with PNx alone.
The present invention, which has been devised to modify a conventional shampoo, relates to a method for producing a shampoo using a red ginseng extract, and a shampoo produced by using the method. Specifically, the oxidation of maltol, which is a skin antiaging ingredient contained in a red ginseng, is reduced with a special method, and an extracted extract is used as a main raw material, and an herbal medicinal agent which is effective in preventing a hair loss and promoting hair growth is mixed. Thus, while a hair loss is prevented by preventing the aging of a scalp, nutrients can be supplied to hair through an herbal medicinal agent which is effective in preventing a hair loss and promoting hair growth. A shampoo using a red ginseng maltol extract according to the present invention is produced as follows. After crushing red ginseng into powder, an ethanol solution in which a ratio of ethanol to water is 55-70% and red ginseng powder are added to a heating tank to be heated at a temperature of 75-85°C for 1 hour or longer. Together with licorice, an extract obtained by extracting and cooling red ginseng maltol in an extraction tank, and an herbal medicinal extract extracted by adding and heating sweet flags, Pleuropterus multiflorus TURCZ., Portulaca extracts, Schizandra chinensis (Turcz.) Baillon, Artemisia argyi Lev. et Vant. leaves, green tea leaves, and Asian lizard′s tail in purified water are added to a spirit and heated at 80°C for 3 hours. Then, the extract therefrom is mixed with L-menthol and glycerin. According to the present invention, a red ginseng maltol ingredient prevents a hair loss by preventing the aging of a scalp, and nutrients can be supplied to hair through an herbal medicinal agent which is effective in preventing a hair loss and promoting hair growth.
The invention relates to a test calculation method adopted for solving a dissolution problem of traditional Chinese drug pill. With the present invention, the following problems are effectively solved: pill dissolution, assurance of dissolution of active ingredients in the pill, and assurance of therapeutic effect. The technical scheme for solving the problems is: determining a formulation of the pill according to clinical requirements, wherein the formulation comprises a general preparation, a slow release preparation, a long-acting preparation and the like; analyzing whether traditional Chinese drug materials in the pill prescription have significant assistant functions and functional properties; preparing a model drug through calculating the ratios of the materials, then carrying out a dissolution experiment; calculating the dissolution and the dissolution parameters, establishing a non-linear mathematical model to obtain the related material parameters; processing the materials according to the material parameters, preparing the pill and verifying the material parameters; adjusting the parameters, calculating the material ratio of the pill. The method provided by the present invention is simple, and is easy to be used. With the method, the optimal formula of the drug composition is effectively solved, the dissolution of the pill and the efficacy of pill are ensured. Therefore, the method is a major innovation in the development of the traditional Chinese drug.
It is a randomized intra-individual comparative study where two areas of the skin are ablated using an erbium YAG laser at Visit 1, with a surface area of approximately 6cm² (Z1 and Z3). Additionally, two healthy areas (Z2 and Z4), with a similar surface area, are identified on each forearm. The study involves comparing the areas treated with the product RV1551P GB3224 to the untreated areas (randomized arms).
Microneedle electrode array placed into dermis for up to 3 days. DPV Scans performed at a frequency of 1-20 per hour.
A cosmetic product comprising a solid mass of cosmetic material and a body (20) is formed in the body by application of suction to a slurry of the cosmetic material contained in a tapered cavity (22) in the body. Heat may be applied to effect drying, either simultaneously with or subsequent to the application of suction. The cavity (22) tapers in cross-section to its open top (24), through which the cosmetic material is exposed in the cosmetic product. A porous membrane (18) supported by an apertured surface (10) contacts the cosmetic material during application of suction and provides a textured surface in the cosmetic product. The material is retained in the body (20) by application of adhesive to the material and the body in the region of the open bottom (26) of the body. The slurry comprises cosmetic substances, for example colourant and filler, a resin, fat, wax or oil as a binder and one or more materials dissolving or emulsifying the binder.
The invention discloses a Tibetan medicine composition. The Tibetan medicine composition comprises 40 to 60 parts of dry seeds of Sophora moocrofiiana(Benth.) Baker, 5 to 15 parts of crocus sativus L., 25 to 35 parts of dry whole herbs of Saussurea medusa Maxim. or S. laniceps Hand Mazz., 3 to 12 parts of dry tuberous roots of Aconitum flavum Hand.-Mazz. and A. pendulum Busch., 40 to 50 parts of Tinosporasinensis(Lour.)Merr., 35 to 55 parts of dry roots of Mirabilis himalaica (Edgew.)Heim., and 2 to 10 parts of himalayana marmota oil. The Tibetan medicine composition has functions of inflammation-diminishing, pain-relieving, sterilization and itching-relieving. The invention also provides a use of the Tibetan medicine composition in preparation of drugs and sanitary products for inflammation-diminishing, pain-relieving, sterilization and itching-relieving. The Tibetan medicine composition as an active component and pharmaceutically acceptable auxiliary materials can be prepared into corresponding medicinal preparations and especially can be prepared into all dosage forms of externally-applied drugs especially such as a liquid externally-applied drug. The Tibetan medicine composition can effectively resist and relieve a part of human body pathological changes caused by Gram-negative bacteria and Gram-positive bacteria, and has obviously medical treatment and public health purposes of inflammation-diminishing, pain-relieving, sterilization and itching-relieving. Preparation methods of various dosage forms of preparations of the Tibetan medicine composition are simple and can be controlled easily.
Patients in this group will spit into 1.5 ml tubes at 15:30 in the morning before starting the impacted tooth surgery and 48 hours after the surgery, and these tubes will be stored in the refrigerator at -22 degrees. The samples in these tubes will then be examined with ELISA kits and the numerical data of adrenal glucocorticoids in the saliva will be obtained. The patients will fill out the Visual Analog Scale and OHIP-14 forms a total of five times: 6 hours, 24 hours, 48 hours, 72 hours and 7 days after the surgery.
The 8-week inspiratory muscle training protocol consists of using 80% of maximal inspiratory pressure (determined in lab), 3x per week, 6 sets of 6 repetitions. Each set will be separated by decreasing lengths of time over the 8 weeks starting at a 30 second interim. This totals 36 inhalations 3 times per week. Progress will be determined via weekly phone calls with the participants and progress will also be logged by participants over the 8 weeks.
Several French studies on crizotinib have been conducted in recent years. These are not only patients treated in the PROFILE 1005 and 1007 clinical studies but also patients who have been treated with crizotinib in the named patient ATU followed by the cohort ATU (Expended Access Cohort). Under the ATU program and according to ATU regulations, a limited set of data is collected and furthermore the follow up is stopped as soon as the ATU program closes. Thus it is not possible to have access to long term data and post progression data. Our project is to collect data from the patients from the ATU program (named patient and cohort) and if possible patients treated after the marketing of crizotinib, before, during and after crizotinib therapy. Centers selected for this observational study will be those of the IFCT network that took part in the ATU program.

This will allow an accurate analysis of crizotinib therapy under "real life" conditions. It should be emphasized that this information is generally neither available from clinical trials nor from ATU programs.
BACKGROUND: Particulate matter (PM) and air pollution have been suggested to be associated with chronic obstructive pulmonary disease (COPD), contributing significantly to global respiratory disease-related mortality. This study aimed to investigate whether seasonal exposure to PM influences dysbiosis in the respiratory microbiota of patients with COPD.
METHODS: Sputum samples were collected four times over 1 year from 102 patients with COPD, and 16S rRNA sequencing was performed. The dynamics of the airway microbiota were analyzed depending on PM exposure levels and season.
RESULTS: The PM-low exposure group had higher α-diversity compared to the PM-high exposure group, particularly noted in spring. Some bacterial groups, including seven species such as Treponema socranskii, were more abundant in the low exposure group. Additionally, the bacterial community structure in summer significantly differed from that in other seasons, with significantly increased α-diversity in this season. The difference in the airway microbiome due to PM exposure was prominent in patients with moderate COPD.
CONCLUSIONS: PM exposure may influence changes in the sputum microbiome depending on exposure levels and seasonal variations. Our results suggest that airway microbiomes could vary with PM exposure according to seasonal trends.
Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
Many patients are now diagnosed with breast fibroadenomas. These are generally detected during breast self-exams, or annual physicals as a smooth, rubbery, oval/elliptical lump in the breast. These patients then go on to receive mammograms, sonograms and usually a core biopsy for the differential diagnosis of benign disease (fibroadenoma) vs breast cancer. Although fibroadenomas are benign, they can be of great concern to the patient because of their ability to mask the presence of other lumps in the breast, they can be painful, cause a physical deformity of the breast or have other symptoms. The current treatment is surgical excision. Surgical removal is invasive and may be cosmetically undesirable to some patients. It would be advantageous to develop a non-invasive ablative method for treatment of this disease. Measures of the clinical success of patients who elect surgical removal of fibroadenomas are generally subjective, and evaluated primarily by the patient (lack of palpable lesion, pain free, and an acceptable cosmetic result). A non-randomized study is proposed to allow for a more practical approach in subject recruitment. Analysis on safety and efficacy will be performed through the use of MRI evaluation and physical exams.
An acquired impairment in writing, also known as agraphia, is a characteristic symptom of aphasia, i.e., a language disorder resulting from damage to the language centers of the brain. Written communication via text and instant messaging, electronic mail, and various types of social media has become an increasingly important part of everyday life in our technology driven society. Consequently, difficulty with written expression can significantly restrict people with aphasia from participation in community life, including social, professional, and educational realms. Improving writing in persons with aphasia could improve communication, increase access to information, reduce isolation and facilitate social connectedness. Furthermore, delivering writing treatment via an electronic modality, such as texting, could be particularly advantageous given the increasing reliance on electronic communication. This study investigates the efficacy of T-WRITE, a computer-based writing treatment for aphasia that targets phrase/sentence level writing using texting. Its aims are to: 1) evaluate the efficacy of computer-based texting treatment for improving written communication in persons with aphasia and 2) assess the extent to which improvements in electronic written communication impact social connectedness and health-related quality of life (HRQOL). This will be accomplished via a randomized controlled trial across two sites that compares computer-based texting treatment (T-WRITE) to a control group that receives a hand-writing treatment (ORLA+WTG).

The intervention is delivered via computer using state-of-the-art virtual therapist technology. A perceptive, life-like animated computer agent (virtual therapist), using visible speech, guides the participant so he or she can independently work through the set of choral reading and writing activities (see figure above showing a screen shot of the virtual therapist). The objective is to assure an optimal learning experience in the comfort of the participant's home by using a virtual therapist with accurate visible speech feedback. The virtual therapist reads aloud, speaks with accurate visible speech, highlights and repeats words and sentences, directs the participant to copy/write phrases or sentences, and provides guidance much like a real therapist. The sequence of steps in the ORLA+WTG and the T-WRITE treatments are identical. The output modality for participants randomized to T-WRITE is texting using a cellular phone whereas participants in the ORLA+WTG will hand-write their responses using pen and paper. Participants will practice their writing for 90 minutes a day, 6 days a week for 4 weeks.
PURPOSE: A pharmaceutical composition containing a Dipterocarpus obtusifolius Teijsm. Ex Miq. extract for preventing or treating inflammatory diseases or allergic diseases is provided to NO and PGE2 generation and to suppress iNOS and COX-2 expression. CONSTITUTION: A pharmaceutical composition for preventing and treating inflammatory diseases contains a Dipterocarpus obtusifolius Teijsm. Ex Miq. extract as an active ingredient. The extract is prepared using water, low carbon number alcohol of C1-C2, or a mixture thereof. A health functional food for preventing and treating inflammatory diseases contains the extract as an active ingredient. A pharmaceutical composition for preventing and treating allergic diseases contains the extract as an active ingredient. A food for preventing and treating allergic diseases contains the extract as an active ingredient.
Group B will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group B will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group B will watch the standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
OBJECTIVE: Protracted febrile myalgia syndrome (PFMS) is characterized by severe myalgia, fever, abdominal pain, and arthralgia/arthritis episodes lasting for several weeks in patients with familial Mediterranean fever. Treatment options include nonsteroidal anti-inflammatory drugs, corticosteroids, and anti-interleukin-1 therapy. This study aimed to share our experiences of PFMS so as to shed light on this rare and elusive condition.
METHODS: This cross-sectional analysis included 17 patients diagnosed with PFMS at our pediatric rheumatology clinic between January 2018 and September 2023.
RESULTS: In our clinic, 17 (1%) of 1663 familial Mediterranean fever patients presented with PFMS, and it was the initial manifestation in 10 patients (58.8%) in the cohort. Eight of the 17 patients had an M694V homozygous mutation in the MEFV gene. A magnetic resonance imaging showed myositis and fasciitis in just 1 patient, and myositis alone was evident in 5 others. Symptoms improved in 2 patients with nonsteroidal anti-inflammatory drugs, whereas prednisolone improved symptoms in 12 patients and anakinra was required in 3 patients. Patients who received anakinra had another severe attack and required long-term anakinra or canakinumab.
CONCLUSIONS: Syndrome for PFMS is difficult to recognize as it can sometimes be the first manifestation of familial Mediterranean fever. The syndrome is not accompanied by fever in some patients, even though the word febrile is part of its name. Most patients respond dramatically to nonsteroidal anti-inflammatory drugs or corticosteroids. In some patients with PFMS, long-term anakinra or canakinumab treatment may be more useful in preventing severe attacks of PFMS than short-term (5 to 7 days) anakinra treatment.
Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks. Additionally, patients undergo chest X-ray, CT or MRI, ultrasound, echocardiography, and blood sample collection throughout the study.
The outbreak of COVID-19 is a worldwide concern. To our knowledge, the details of the hemodynamic characteristics of COVID-19 patients have not yet been well described. Besides, the cardiac injury was reported in about 7-17% of hospitalized patients with COVID-19 in previous Chinese publications and is much more common in patients admitted to ICU and non-survivors. However, no systematic assessment, including echocardiography evaluating the left ventricular function of these patients has been declared. In addition, extravascular lung water (EVLW) and pulmonary capillary permeability are two hall markers in ARDS patient's management, and transpulmonary thermodilution is a validated method to provide these values at the bedside. However, no study has reported the characteristic profile of these variables during ARDS caused by SARS-Cov2. A better knowledge of these characteristics would also be helpful in guiding their management.
Patients receive SJG-136 IV over 20 minutes on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Background: The use of cardiopulmonary bypass during cardiac surgery negatively affects the coagulation system. Hypothermia is also known to inhibit the coagulation profile. The aim of the study is to assess and compare the early postoperative (PO) haematological and coagulation profile of patients undergoing coronary artery bypass graft (CABG) surgery with Hypothermic (HT) versus normothermic (NT) bypass Methods: eighty-six patients were divided into two equal groups: NT group included patients received warm bypass and using warm blood cardioplegia from bypass and HT group included patients received cold bypass and using cold cardioplegia given by the anaesthesiologist. PO monitoring included the activated clotting time (ACT) prior to wound closure and 2-hr changes in the haemoglobin concentration (Hb), platelet count (PC), ADP-induced platelet aggregation (IPA), INR in relation to preoperative profile and amount of PO daily blood loss and number of transfused blood units. The primary outcome was the PO alternations in the coagulation and haematological profile. The secondary outcome was the amount of PO daily bleeding, number of transfused blood units and incidence of re-opening surgery due to bleeding.
Numerous neuroprotectants have been effective when given prior to ischemic stroke in animals, yet they have all have failed when given after ischemic stroke in humans. A novel approach to ischemic neuroprotection is needed. Many patients who undergo cardiac, vascular, and neurosurgical procedures develop ischemic central nervous system (CNS) complications. These high risk surgeries present a unique opportunity to administer neuroprotectant medication prior to the injury, greatly increasing the likelihood that it will have a positive impact on outcomes. Patients undergoing descending thoracic aortic (DTA) and thoracoabdominal aortic (TAA) surgery have a particularly high rate of both brain and spine ischemia. In addition, these surgeries require placement of a lumbar cerebrospinal fluid (CSF) drain, allowing access to CSF in order to monitor markers of injury and penetration of medication into the CNS. We performed a pilot dose finding trial of prophylactic darbepoetin alfa, a long-acting erythropoiesis medication with putative neuroprotectant properties, in patients undergoing DTA and TAA surgery. This dose finding trial was stopped early after 9 patients were enrolled at the request of the FDA after an unrelated trial of erythropoietin in acute stroke performed in Germany was negative and showed possible harm in those patients who received intravenous tissue plasminogen activaor (tPA). We then enrolled 9 additional patients who did not receive any intervention in order to compare them to the patients who received darbepoetin.